Camp4 (CAMP) CSO Daniel Tardiff Sells 1,738 Shares

What Happened
Daniel Tardiff, Chief Scientific Officer of Camp4 Therapeutics (CAMP), reported an open-market sale of 1,738 shares on August 19, 2026. The shares were sold at $4.76 per share for total proceeds of $8,273. This transaction is a sale (not a purchase or option exercise).

Key Details

• Transaction date: 2026-08-19; price: $4.76 per share; shares sold: 1,738; proceeds: $8,273.
• Amount owned following the reported transaction: not disclosed in this Form 4.
• Footnote: The shares sold were originally acquired under Camp4’s Employee Stock Purchase Plan (ESPP) for the Jan 1–Jun 30, 2026 purchase period; the acquisition was exempt under Rule 16b-3(c).
• Filing date / Period of report: 2026-08-19 (no indication the filing was late).

Context
This was a sale of shares previously purchased through the company ESPP. Sales of small dollar amounts by executives (here about $8.3K) are often routine transactions; the filing documents the sale but does not state any change in insider ownership strategy.